Literature DB >> 8620533

The FHIT gene 3p14.2 is abnormal in lung cancer.

G Sozzi1, M L Veronese, M Negrini, R Baffa, M G Cotticelli, H Inoue, S Tornielli, S Pilotti, L De Gregorio, U Pastorino, M A Pierotti, M Ohta, K Huebner, C M Croce.   

Abstract

To determine the role of the FHIT gene, which encompasses the fragile site at 3p14.2, we analyzed 59 tumors of the small cell and non-small cell type by reverse transcription of FHIT mRNA, followed by PCR amplification and sequencing of products. Allelic losses affecting the gene were evaluated by microsatellite polymorphism analysis and genomic alterations by hybridization using cDNA and genomic probes. Small cell lung tumors (80%) and non-small cell lung cancers (40%) showed abnormalities in RNA transcripts of FHIT, and 76% of the tumors exhibited loss of FHIT alleles. Abnormal lung tumor transcripts lack two or more exons of the FHIT gene. Small cell lung cancer tumors and cell lines were analyzed by Southern blotting and showed rearranged BamHI fragments. These data suggest a critical role of the FHIT gene in lung carcinogenesis.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8620533     DOI: 10.1016/s0092-8674(00)81078-8

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  91 in total

1.  Establishment and characterization of nine human brain tumor cell lines.

Authors:  K H Shin; G Choe; Y J Park; J H Jang; H W Jung; J G Park
Journal:  In Vitro Cell Dev Biol Anim       Date:  2001 Nov-Dec       Impact factor: 2.416

Review 2.  Molecular genetic abnormalities in the pathogenesis of human lung cancer.

Authors:  E Forgacs; S Zöchbauer-Müller; E Oláh; J D Minna
Journal:  Pathol Oncol Res       Date:  2001       Impact factor: 3.201

3.  Sequence conservation at human and mouse orthologous common fragile regions, FRA3B/FHIT and Fra14A2/Fhit.

Authors:  T Shiraishi; T Druck; K Mimori; J Flomenberg; L Berk; H Alder; W Miller; K Huebner; C M Croce
Journal:  Proc Natl Acad Sci U S A       Date:  2001-04-24       Impact factor: 11.205

4.  DNA hypermethylation profiles in squamous cell carcinoma of the vulva.

Authors:  Josena K Stephen; Kang Mei Chen; Misa Raitanen; Seija Grénman; Maria J Worsham
Journal:  Int J Gynecol Pathol       Date:  2009-01       Impact factor: 2.762

Review 5.  Lung cancer. 9: Molecular biology of lung cancer: clinical implications.

Authors:  K M Fong; Y Sekido; A F Gazdar; J D Minna
Journal:  Thorax       Date:  2003-10       Impact factor: 9.139

6.  Absence of FHIT expression is associated with apoptosis inhibition in colorectal cancer.

Authors:  Jie Cao; Xiaoping Chen; Wanglin Li; Jie Xia; Hong Du; Weibiao Tang; Shanming Chen; Hui Wang; Xiwen Chen; Huanqing Xiao; Yuyuan Li
Journal:  Front Med China       Date:  2007-05-01

7.  Fragile histidine triad gene alterations are not essential for hepatocellular carcinoma development in South Korea.

Authors:  Chang-Woo Nam; Jung-Woo Shin; Neung-Hwa Park
Journal:  World J Gastroenterol       Date:  2008-06-14       Impact factor: 5.742

8.  Aberrant gene expression in human non small cell lung carcinoma cells exposed to demethylating agent 5-aza-2'-deoxycytidine.

Authors:  Bao-Zhu Yuan; Amy M Jefferson; Nicholas C Popescu; Steven H Reynolds
Journal:  Neoplasia       Date:  2004 Jul-Aug       Impact factor: 5.715

9.  Designed FHIT alleles establish that Fhit-induced apoptosis in cancer cells is limited by substrate binding.

Authors:  Francesco Trapasso; Agnieszka Krakowiak; Rossano Cesari; Jeffrey Arkles; Sai Yendamuri; Hideshi Ishii; Andrea Vecchione; Tamotsu Kuroki; Pawel Bieganowski; Helen C Pace; Kay Huebner; Carlo M Croce; Charles Brenner
Journal:  Proc Natl Acad Sci U S A       Date:  2003-02-06       Impact factor: 11.205

10.  Chromosome 3p loss of heterozygosity and mutation analysis of the FHIT and beta-cat genes in squamous cell carcinoma of the head and neck.

Authors:  M V González; M F Pello; P Ablanedo; C Suárez; V Alvarez; E Coto
Journal:  J Clin Pathol       Date:  1998-07       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.